Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Dr Lalchandani Labs Ltd - 541299 - Audited Financial Results For The Half Year Ended On 31St March, 2020 And Year Ended On 31St March, 2020

 Dr Lalchandani Labs Limited wish to inform you that the Board of the Company at its meeting held today, inter alia has transacted the following: 1. Statement showing the Audited Financial Statement Result for the half year and year ended 31st March, 2020 along with Auditors Report on Audited Financial Results is also enclosed herewith, and 2. In Compliance with Regulation 33(3)(d) of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/56/2016 date 27th May, 2016 we declare that report of Statutory Auditor is with unmodified opinion with respect to the Audited Financial Result of the Company for the half year and year ended 31st March, 2020. 3. Appointment of M/s Heena Taneja and Associates, Company Secretaries, as a Secretarial Auditor and Scrutinizer for the Financial Year 2019-2020. 4. Disclosure of impact of COVID-19 pandemic. Kindly take the same on record and acknowledge.
28-07-2020
Bigul

Dr Lalchandani Labs Ltd - 541299 - Outcome Of The Board Meeting Dated 28.07.2020

 Dr Lalchandani Labs Limited wish to inform you that the Board of the Company at its meeting held today, inter alia has transacted the following: 1. Statement showing the Audited Financial Statement Result for the half year and year ended 31st March, 2020 along with Auditors Report on Audited Financial Results is also enclosed herewith, and 2. In Compliance with Regulation 33(3)(d) of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/56/2016 date 27th May, 2016 we declare that report of Statutory Auditor is with unmodified opinion with respect to the Audited Financial Result of the Company for the half year and year ended 31st March, 2020. 3. Appointment of M/s Heena Taneja and Associates, Company Secretaries, as a Secretarial Auditor and Scrutinizer for the Financial Year 2019-2020. 4. Disclosure of impact of COVID-19 pandemic. Kindly take the same on record and acknowledge.
28-07-2020
Bigul

Dr Lalchandani Labs Ltd - 541299 - Board Meeting Intimation for Board Meeting Intimation For The Audited Financial Results Of The Company For The Financial Year Ended March 31, 2020.

 Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2020 ,inter alia, to consider and approve DR LALCHANDANI LABS LIMITED has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2020, inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2020.
22-07-2020
Bigul

Dr Lalchandani Labs Ltd - 541299 - Announcement Under Regulation 30 (LODR)-Announcement Regarding Approval Of ICMR For Covid-19 RT-PCR Testing.

 We are glad to announce that 'Dr Lalchandani Labs Limited' have successfully obtain the approval from Indian Council of Medical Research [ICMR] for COVID -19 RT-PCR testing.
20-07-2020
Bigul

Dr Lalchandani Labs Ltd - 541299 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Certificate under Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended 30th June 2020
15-07-2020
Bigul

Dr Lalchandani Labs Ltd - 541299 - Statement Of Investor Complaints For The Quarter Ended June 2020

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- SWATI PODDARDesignation :- Company Secretary and Compliance Officer
15-07-2020
Bigul

Dr Lalchandani Labs Ltd - 541299 - Cancellation of Board Meeting

 The Board Meeting to be held on 30/06/2020 Stands Cancelled.
29-06-2020
Bigul

Dr Lalchandani Labs Ltd - 541299 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayDr Lalchandani Labs Ltd 2CINL85320DL2017PLC321605 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: SWATI PODDAR Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: [email protected] Name of the Chief Financial Officer: Mrs ANCHAL GUPTA Designation: DIRECTOR AND CHIEF FINANCIAL OFFICER EmailId: [email protected] Date: 26/06/2020 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
26-06-2020
Bigul

Dr Lalchandani Labs Ltd - 541299 - Non-Applicability Certificate For Corporate Governance And Annual Secretarial Compliance Report.

 We state that the Company is listed on the Small and Medium Enterprise (SME) platform of Bombay Stock Exchange Limited and hence as per Regulation 15(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the compliance with the corporate governance provisions and submission of related reports, as amended from time to time and mentioned therein are not applicable to the Company. In view of the above and as per the circular no. LIST/COMP/12/2019-20 dated 14th May 2019 of Bombay Stock Exchange Limited, we would like to state that the Company is not required to submit Annual Secretarial Compliance Report vide circular CIR/CFD/CMD1/27/2019 dated 08th February 2019 of Securities and Exchange Board of India and Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
26-06-2020
Bigul

Dr Lalchandani Labs Ltd - 541299 - Board Meeting Intimation for Board Meeting Intimation For The Audited Financial Results Of The Company For The Financial Year Ended March 31, 2020.

 Dr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/06/2020 ,inter alia, to consider and approve DR LALCHANDANI LABS LIMITED has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/06/2020, inter alia, to consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2020.
23-06-2020
Next Page
Close

Let's Open Free Demat Account